Key result
Cumulative doxorubicin exposure up to 500 mg/m2 in adult lymphoma patients significantly decreased LVEF from 58.1% to 49.3% (P<0.001) and was associated with early sympathetic predominance.
Why the study?
What are the neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients?
Population
27 adult lymphoma patients
Comparison
Doxorubicin therapy vs Baseline measurements
Design
Cohort
Follow-up
Until cumulative doxorubicin dose of 500 mg/m2
Authors
Loading...
Early sympathetic predominance may mark incipient doxorubicin cardiotoxicity; hypothesis-generating for neuroendocrine monitoring in lymphoma patients.
Observational (n=27)
What are the neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients?
Absolute Event Rate: 49.3% vs 58.1%
p-value: p=<0.001
Doxorubicin-induced left ventricular dysfunction is associated with an early shift towards sympathetic predominance, followed by attenuation possibly due to increased natriuretic peptide secretion.
Nousiainen et al. (2001) conducted an observational in Lymphoma (doxorubicin-induced cardiotoxicity) (n=27). Doxorubicin vs. baseline was evaluated on Left ventricular ejection fraction (LVEF) (p=<0.001). Cumulative doxorubicin exposure up to 500 mg/m2 in adult lymphoma patients significantly decreased LVEF from 58.1% to 49.3% (P<0.001) and was associated with early sympathetic predominance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: